MaaT013 – Steroid-Refractory Acute Graft-Versus-Host Disease (SRaGvHD) program – enema
|› Evaluation of Complete Response (CR) or Very Good Partial Response (VGPR) of Steroid Refractory, Gastrointestinal, Acute Graft-Versus-Host Disease (SRaGvHD) treated with MaaT013 (pooled donors)||› First Patient In (FPI): august 2018
› 3 Positive DSMBs (first 15 Patients) –> Study continuing without amendments
› Readout expected in 1Q 2021
MaaT 033 – Oral Form – improvement of overall survival in hematological patients
What are Hematological Malignancies?
For example, there are 4 major types of leukemia:
- Acute Lymphocytic leukemia
- Chronic Lymphocytic leukemia
- Acute Myeloid Leukemia
- Chronic Myeloid Leukemia
What is the worldwide estimated incidence and mortality (2012) ?
|Incidence (% all cancers)||Mortality (% all cancers)|
|Leukemia||351 965 (2.5%)||265 471 (3.2%)|
|Hodgkin’s Lymphoma||65 950 (0.5%)||25 469 (0.3%)|
|Non-Hodgkin’s Lymphoma||385 741 (2.7%)||199 670 (2.4%)|
|Multiple Myeloma||114 251 (0.8%)||80 019 (1.0%)|
Source – globocan.iarc.fr / 2012
Partnering with MaaT Pharma
to accelerate the access of our drugs to patients.
We are constantly looking to explore new frontiers, improve our drugs and improve the preparation of our clinical trials. Therefore, we are open to partnerships with investigator-initiated studies to collect Big Data using our GutPrint® meta genomics platform.